Erasmus MC

Rotterdam, Netherlands

69 recruiting

Showing 120 of 134 trials

Recruiting
Phase 1

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Urinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms
Eli Lilly and Company535 enrolled82 locationsNCT05614739
Recruiting
Phase 3

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

Sickle Cell Disease
Novo Nordisk A/S408 enrolled174 locationsNCT06612268
Recruiting
Phase 3

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

COVID-19 Infection
Pfizer300 enrolled147 locationsNCT07013474
Recruiting
Phase 1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 3

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Metastatic CancerAdvanced Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc.482 enrolled126 locationsNCT05208047
Recruiting
Phase 4

Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer

Cervical Cancer
University Medical Center Groningen261 enrolled11 locationsNCT07645625
Recruiting
Phase 2

Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)

Pompe Disease
Shionogi45 enrolled28 locationsNCT07123155
Recruiting
Phase 2

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

Adenocarcinoma, Pancreatic Ductal
Genentech, Inc.260 enrolled89 locationsNCT05968326
Recruiting
Phase 3

ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer

Rectal Cancer
Erasmus Medical Center103 enrolled25 locationsNCT07188025
Recruiting
Phase 3

Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

First Progression of Glioblastoma
European Organisation for Research and Treatment of Cancer - EORTC411 enrolled45 locationsNCT05904119
Recruiting
Phase 3

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Colorectal Neoplasms
Janssen Research & Development, LLC700 enrolled247 locationsNCT06750094
Recruiting
Phase 3

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Colorectal Neoplasms
Janssen Research & Development, LLC1,000 enrolled237 locationsNCT06662786
Recruiting
Not Applicable

A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE PRO Software in Participants With PsAF

Atrial Fibrillation
Biosense Webster, Inc.50 enrolled10 locationsNCT07428564
Recruiting
Phase 3

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma
Janssen Research & Development, LLC400 enrolled65 locationsNCT07258511
Recruiting
Phase 3

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

NMDAR Autoimmune EncephalitisLGI1 Autoimmune Encephalitis
Hoffmann-La Roche120 enrolled93 locationsNCT05503264
Recruiting
Phase 3

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC220 enrolled109 locationsNCT06919965
Recruiting
Phase 1Phase 2

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

Lymphoma, Non-HodgkinLymphoma, B-CellLymphoma, Large B-Cell, Diffuse
Janssen Research & Development, LLC439 enrolled32 locationsNCT05421663
Recruiting
Phase 3

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Neoplasms
Janssen Research & Development, LLC663 enrolled168 locationsNCT07164443
Recruiting
Phase 2

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

Multiple Myeloma
Janssen Research & Development, LLC210 enrolled38 locationsNCT06500884
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

Muscle-invasive Urothelial Carcinoma
Hoffmann-La Roche62 enrolled107 locationsNCT06534983